Atrial Fibrillation Clinical Trial
Official title:
The Intra-Operative Application of Amiodarone Releasing Hydrogel to Prevent Postoperative Atrial Fibrillation in Patients Undergoing Lung Transplantation
This study will prospectively evaluate the use of an amiodarone releasing hydrogel applied to the pulmonary veins and atria at the time of lung transplantation. This study will include patients undergoing lung transplantation at Jewish Hospital, Louisville KY. The prospective group will be compared to historical controls from the same institution. Investigators will access medical records and database entries for those patients undergoing lung transplantation after January 1st 2005 in order to obtain matched controls for analysis. Informed consent will be obtained from the prospective cohort prior to patient enrollment. This pilot study will be used to obtain preliminary data in order to proceed with a larger randomized control trial.
Approximately 1900 transplants are performed in the US annually. Lung transplantation remains
the gold standard treatment for patients with end stage lung disease. This includes patients
with range of etiologies such as Idiopathic Pulmonary Fibrosis, COPD and Cystic Fibrosis. One
of the more common post-operative complications in patients undergoing lung transplantation
is the development of atrial fibrillation. Recent studies have demonstrated that
approximately 1/3 of patients will develop atrial fibrillation during their post-operative
course. While it is uncertain if the development of post-operative atrial fibrillation
affects survival, it does significantly increase length of hospital stay. Importantly, a
portion of the patients that develop atrial fibrillation post-operatively will require
cardioversion prior to discharge.
Currently one of the main stays of treatment for post-operative atrial fibrillation is
systemic (oral or intravenous) amiodarone, which is a class III antiarrhythmic agent. While
this particular drug is effective, it does carry the risk of several known complications. Due
to the drug's pharmacokinetics, amiodarone concentrates in organs with high lipid content
such as the thyroid, liver and lung. Amiodarone has several known adverse effects on the lung
ranging from acute respiratory distress syndrome to more chronic disease such as Interstitial
pulmonary fibrosis. Amiodarone can have detrimental effects on the liver which in rare cases
could lead to cirrhosis. Additionally, amiodarone can cause thyrotoxicosis as early as a few
weeks after the initiation of amiodarone.
The adverse events listed above are related to the cumulative dose of amiodarone. Typically,
when amiodarone is initiated, patients receive a loading dose of 600-800mg daily until the
cumulative dose reaches 10 grams, after which patients will receive 200mg daily as a
maintenance dose. Minimizing the cumulative dose of amiodarone by using a local application,
could mitigate the potential adverse drug toxicities. In a previous study, the application of
an amiodarone releasing hydrogel performed intraoperatively was shown to significantly
decrease the rates of post-operative atrial fibrillation in patients undergoing coronary
artery bypass. Currently for patients undergoing lung transplantation, there is not a safe
and effective measure available to prevent post-operative atrial fibrillation.
The Investigators aim to study the intraoperative application of an amiodarone containing
hydrogel for prevention of post-operative atrial fibrillation in lung transplant patients.
In patients undergoing lung transplantation, post-operative atrial fibrillation is common and
leads to prolonged hospital course and increased healthcare expenditures. Amiodarone is a
main stay of therapy for atrial fibrillation, however this drug does have potential serious
complications when administered systemically. The local application of amiodarone, could
potentially decrease the rates of atrial fibrillation, while avoiding the systemic
complications. This has the potential to decrease length of stay and decrease additional
procedures (ie. Cardioversion) in patients undergoing lung transplantation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |